OncoCyte Q2 2023 Earnings Report

OncoCyte EPS Results

• Actual EPS: -$1.07
• Consensus EPS: -$2.60
• Beat/Miss: Beat by +$1.53
• One Year Ago EPS: N/A

OncoCyte Revenue Results

• Actual Revenue: $0.46 million
• Expected Revenue: $0.60 million
• Beat/Miss: Missed by -$140.00 thousand
• YoY Revenue Growth: N/A

OncoCyte Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A

OncoCyte (NASDAQ:OCX), a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.